Cargando…

Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case–Control Study Based on the French National Health Data System

BACKGROUND: Knowing the duration of effectiveness of coronavirus disease 2019 (COVID-19) booster doses is essential to providing decision-makers with scientific arguments about the frequency of subsequent injections. We estimated the level of protection against COVID-19-related hospitalizations (Omi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semenzato, Laura, Botton, Jérémie, Le Vu, Stéphane, Jabagi, Marie-Joëlle, Cuenot, François, Drouin, Jérôme, Dray-Spira, Rosemary, Weill, Alain, Zureik, Mahmoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551849/ https://www.ncbi.nlm.nih.gov/pubmed/37808897 http://dx.doi.org/10.1093/ofid/ofad460

Ejemplares similares

Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France
por: Semenzato, Laura, et al.
Publicado: (2022)

Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people
por: Semenzato, Laura, et al.
Publicado: (2021)

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations
por: Botton, Jérémie, et al.
Publicado: (2022)

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study
por: Bouillon, Kim, et al.
Publicado: (2022)

Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines
por: Botton, Jérémie, et al.
Publicado: (2022)

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
por: Le Vu, Stéphane, et al.
Publicado: (2022)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study
por: Bouillon, Kim, et al.
Publicado: (2022)

Design cas témoins apparié sur score de risque : un outil méthodologique original pour une étude de l'efficacité vaccinale et des conséquences médicales de l'hospitalisation pour COVID-19 en France.
por: Semenzato, L., et al.
Publicado: (2023)

A modified self‐controlled case series method for event‐dependent exposures and high event‐related mortality, with application to COVID‐19 vaccine safety
por: Ghebremichael‐Weldeselassie, Yonas, et al.
Publicado: (2022)

Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients
por: Semenzato, Laura, et al.
Publicado: (2021)

Caractéristiques sociodémographiques et médicales associées au risque d’échec d'un schéma vaccinal deux doses contre la COVID-19 en France
por: Semenzato, L., et al.
Publicado: (2022)

Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System
por: Semenzato, Laura, et al.
Publicado: (2022)

8Association entre les vaccins COVID-19 à ARN messager et la survenue de myocardite et péricardite chez les personnes de 12 à 50 ans en France
por: Vu, S. Le, et al.
Publicado: (2022)

No association of low‐dose aspirin with severe COVID‐19 in France: A cohort of 31.1 million people without cardiovascular disease
por: Botton, Jérémie, et al.
Publicado: (2022)

Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines
por: Zureik, Mahmoud, et al.
Publicado: (2023)

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study
por: Mimura, Wataru, et al.
Publicado: (2022)

Effects of the Coronavirus Disease 2019 (COVID-19) Lockdown on the Use of Contraceptives and Ovulation Inductors in France
por: Roland, Noémie, et al.
Publicado: (2021)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa
por: Jassat, Waasila, et al.
Publicado: (2022)

Intravitreal Anti–Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic
por: Billioti de Gage, Sophie, et al.
Publicado: (2020)

Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
por: Roland, Noémie, et al.
Publicado: (2022)

Impact of coronavirus disease 2019 on contraception use in France
por: Roland, Noémie, et al.
Publicado: (2023)

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
por: Junker, Daniel, et al.
Publicado: (2022)

Colonoscopy in France during the COVID-19 pandemic
por: Meyer, Antoine, et al.
Publicado: (2021)

Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1–BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa( )
por: Johnson, Rabia, et al.
Publicado: (2022)

Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France
por: Jabagi, Marie Joelle, et al.
Publicado: (2019)

Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer
por: Jabagi, Marie Joelle, et al.
Publicado: (2019)

Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy
por: Miyauchi, Shunsuke, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study
por: Baerends, Eva A M, et al.
Publicado: (2023)

Impact de l’épidémie COVID-19 sur l'utilisation des contraceptifs en France en 2020 et jusqu'en avril 2021
por: Roland, N., et al.
Publicado: (2022)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
por: Tuan, Jessica J., et al.
Publicado: (2023)

Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters
por: Su, Wen, et al.
Publicado: (2022)

3Estimation de l'impact de la vaccination sur le risque de formes graves de COVID-19 au sein des départements d'Outre-Mer à partir des données du Système national des données de santé (SNDS) - Résultats jusqu'au 30 septembre 2021
por: Semenzato, L., et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

Mandatory Infant Vaccinations in France During the COVID-19 Pandemic in 2020
por: Taine, Marion, et al.
Publicado: (2021)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_spgaupubhp4m167fjf3sri40vg